Key Highlights

  • Viatris agreed on October 8, 2026 to buy Pacira BioSciences (NASDAQ:PCRX) for USD 36.50 per share in cash, an equity value of about USD 1.65 billion, per the joint release and the 8-K filing.
  • Pacira (NASDAQ:PCRX) closed at USD 36.39, up 44.4%, just under the offer price, which suggests investors see a high chance that the deal closes and little chance of a higher bid.
  • Pacira brings Exparel and Zilretta, which together produced about USD 746 million of trailing revenue, to a buyer seeking non-opioid pain products, and that revenue base is the core of what Viatris is paying for.
  • Viatris (NASDAQ:VTRS) fell about 1.7% to 3%, and Oppenheimer cut Pacira to Perform, a move that follows the price reaching the offer and removes near-term upside from the rating.

The Terms

Viatris and Pacira announced a definitive agreement on October 8, 2026, under which Viatris will pay USD 36.50 per share in cash for Pacira, an equity value of about USD 1.65 billion. The 8-K text confirms the price and structure. Pacira (NASDAQ:PCRX) closed at USD 36.39, which is 44.4% higher, so the market price sits about 0.3% below the offer, simple arithmetic on two published numbers. A narrow gap usually signals that traders expect the deal to close, and the remaining discount pays for time and risk. The transaction still needs customary approvals and a shareholder process, and a timeline beyond the announcement should be checked in the filing, since closing dates can slip.

What Viatris Gets

Pacira sells Exparel, a long-acting local anesthetic used during surgery, and Zilretta, an injection for knee osteoarthritis pain. Together they generated about USD 746 million in trailing revenue. Both fit the market for pain treatments that avoid opioids, a category hospitals and regulators favor. Viatris (NASDAQ:VTRS) is a generics and branded drug company that has been rebalancing its portfolio, so adding branded, hospital-based products broadens its mix and could lift margins if integration goes well. Viatris shares fell about 1.7% to 3% on the news, which indicates some investors worry about price paid, integration, or leverage. Oppenheimer cut Pacira (NASDAQ:PCRX) to Perform because the offer caps near-term upside. Analysts often move to neutral ratings once a cash price is set.

Risks and What to Watch

Deal risk is the main uncertainty. Regulators could review the transaction, shareholders could object to the price, and financing or integration problems could appear at Viatris. If the deal breaks, Pacira (NASDAQ:PCRX) could fall toward its pre-announcement level. The product risk is also real, since Exparel faces competition from other non-opioid options and from generic pressure over time. Watch for the merger proxy, antitrust filings, any competing bid, a closing date, regulatory clearance, and Viatris commentary on funding and synergies. The small spread between the stock price and the offer is a market judgment, not a guarantee, and it can widen quickly on any regulatory surprise.

Where Things Stand

Pacira jumped because Viatris agreed to pay USD 36.50 in cash, a large premium to the prior price, and the stock now trades just under the offer. Pacira (NASDAQ:PCRX) holders get a clear exit price if the deal closes, which is why upside beyond it is limited. Viatris must show that the purchase of Exparel and Zilretta adds value. The next steps are regulatory review, shareholder approval and the closing timeline.